AURA · Aura Biosciences, Inc. · Financials
Market Cap
$726.97M
Shares
103.70M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$106.19M
-22.2%
FY2025
Diluted EPS
-$1.76
-0.6%
FY2025
Operating Cash Flow
-$84.74M
-6.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $102.78M | $90.3M | $73.3M | $65.23M | $42.24M | $25.16M | $18.04M | |
| $35.29M | $22.49M | $22.81M | $19.76M | $18.06M | $10.09M | $4.16M | |
| -$138.08M | -$112.79M | -$96.12M | -$84.99M | -$60.3M | -$35.25M | -$22.21M | |
| $7.15M | $6.71M | $9.31M | $8.72M | $1.53M | -$1000 | — | |
| — | — | — | — | -$9000 | — | — | |
| -$130.93M | -$106.08M | -$86.81M | -$76.27M | -$58.76M | — | — | |
| $82K | $108K | $112K | $137K | $0 | $0 | $0 | |
| -$131.01M | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -$35.25M | -$22.21M | |
| -$131.71M | -$106.56M | -$87.2M | -$75.8M | -$58.84M | -$35.25M | — | |
| USD/shares | -$1.72 | -$1.76 | -$1.75 | -$1.93 | -$1.96 | -$8.95 | — |
| USD/shares | -$1.72 | -$1.76 | -$1.75 | -$1.93 | -$1.96 | -$8.95 | — |
| shares | — | 60.34M | 49.65M | 39.62M | 29.94M | 5.16M | 367.2K |
| shares | — | 60.34M | 49.65M | 39.62M | 29.94M | 5.16M | 367.2K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.55×
EV/EBIT
—
Peer median 10.93×
P/E (TTM)
—
Peer median 13.19×
Peer medians compare against the 304 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1501796
CUSIP
05153U107
13F (30d)
87 filings
87 filers
Visit website
Investor relations